---
document_datetime: 2025-12-02 04:50:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-sun.html
document_name: sitagliptin-sun.html
version: success
processing_time: 0.1024258
conversion_datetime: 2025-12-24 08:46:32.438774
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sitagliptin SUN

[RSS](/en/individual-human-medicine.xml/67502)

##### Authorised

This medicine is authorised for use in the European Union

sitagliptin fumarate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sitagliptin SUN](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sitagliptin SUN is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used together with diet and exercise in the following ways:

- on its own, in patients whose blood glucose levels are not satisfactorily controlled with diet and exercise and who cannot take metformin (a diabetes medicine);
- in combination with metformin or a PPAR-gamma agonist (a type of diabetes medicine) such as a thiazolidinedione, in patients whose blood glucose levels are not satisfactorily controlled with metformin or the PPAR-gamma agonist used on its own;
- in combination with a sulphonylurea (another diabetes medicine) in patients whose blood glucose levels are not satisfactorily controlled with a sulphonylurea used on its own and who cannot take metformin;
- in combination with both metformin and a sulphonylurea or a PPAR-gamma agonist, in patients whose blood glucose levels are not satisfactorily controlled with the two medicines;
- in combination with insulin, with or without metformin, in patients whose blood glucose levels are not satisfactorily controlled with a stable dose of insulin.

Sitagliptin SUN contains the active substance sitagliptin and is a 'generic medicine'. This means that Sitagliptin SUN contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Januvia. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Sitagliptin SUN used?

Sitagliptin SUN is available as tablets and can only be obtained with a prescription. The recommended dose is 100 mg once a day. The dose may be lowered in some patients with reduced kidney function. If Sitagliptin SUN is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood glucose levels).

For more information about using Sitagliptin SUN, see the package leaflet or contact your doctor or pharmacist.

## How does Sitagliptin SUN work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Sitagliptin SUN, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of 'incretin' hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Sitagliptin does not work when blood glucose levels are low. Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Together, these processes reduce blood glucose levels and help to control type 2 diabetes.

## How has Sitagliptin SUN been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Januvia, and do not need to be repeated for Sitagliptin SUN.

As for every medicine, the company provided data on the quality of Sitagliptin SUN. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Sitagliptin SUN?

Because Sitagliptin SUN is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sitagliptin SUN authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sitagliptin SUN has been shown to have comparable quality and to be bioequivalent to Januvia. Therefore, the Agency's view was that, as for Januvia, the benefits of Sitagliptin SUN outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sitagliptin SUN?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sitagliptin SUN have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sitagliptin SUN are continuously monitored. Suspected side effects reported with Sitagliptin SUN are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sitagliptin SUN

Sitagliptin SUN received a marketing authorisation valid throughout the EU on 09 December 2021.

Sitagliptin SUN : EPAR - Medicine overview

Reference Number: EMA/604084/2021

English (EN) (168.09 KB - PDF)

**First published:** 17/01/2022

[View](/en/documents/overview/sitagliptin-sun-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-555)

български (BG) (192.6 KB - PDF)

**First published:**

17/01/2022

[View](/bg/documents/overview/sitagliptin-sun-epar-medicine-overview_bg.pdf)

español (ES) (168.6 KB - PDF)

**First published:**

17/01/2022

[View](/es/documents/overview/sitagliptin-sun-epar-medicine-overview_es.pdf)

čeština (CS) (188.82 KB - PDF)

**First published:**

17/01/2022

[View](/cs/documents/overview/sitagliptin-sun-epar-medicine-overview_cs.pdf)

dansk (DA) (167.65 KB - PDF)

**First published:**

17/01/2022

[View](/da/documents/overview/sitagliptin-sun-epar-medicine-overview_da.pdf)

Deutsch (DE) (171.41 KB - PDF)

**First published:**

17/01/2022

[View](/de/documents/overview/sitagliptin-sun-epar-medicine-overview_de.pdf)

eesti keel (ET) (168.27 KB - PDF)

**First published:**

17/01/2022

[View](/et/documents/overview/sitagliptin-sun-epar-medicine-overview_et.pdf)

ελληνικά (EL) (212.35 KB - PDF)

**First published:**

17/01/2022

[View](/el/documents/overview/sitagliptin-sun-epar-medicine-overview_el.pdf)

français (FR) (170.07 KB - PDF)

**First published:**

17/01/2022

[View](/fr/documents/overview/sitagliptin-sun-epar-medicine-overview_fr.pdf)

hrvatski (HR) (186.84 KB - PDF)

**First published:**

17/01/2022

[View](/hr/documents/overview/sitagliptin-sun-epar-medicine-overview_hr.pdf)

italiano (IT) (167.13 KB - PDF)

**First published:**

17/01/2022

[View](/it/documents/overview/sitagliptin-sun-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (205.56 KB - PDF)

**First published:**

17/01/2022

[View](/lv/documents/overview/sitagliptin-sun-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (206.62 KB - PDF)

**First published:**

17/01/2022

[View](/lt/documents/overview/sitagliptin-sun-epar-medicine-overview_lt.pdf)

magyar (HU) (189.75 KB - PDF)

**First published:**

17/01/2022

[View](/hu/documents/overview/sitagliptin-sun-epar-medicine-overview_hu.pdf)

Malti (MT) (193.14 KB - PDF)

**First published:**

17/01/2022

[View](/mt/documents/overview/sitagliptin-sun-epar-medicine-overview_mt.pdf)

Nederlands (NL) (168.87 KB - PDF)

**First published:**

17/01/2022

[View](/nl/documents/overview/sitagliptin-sun-epar-medicine-overview_nl.pdf)

polski (PL) (192.64 KB - PDF)

**First published:**

17/01/2022

[View](/pl/documents/overview/sitagliptin-sun-epar-medicine-overview_pl.pdf)

português (PT) (168.8 KB - PDF)

**First published:**

17/01/2022

[View](/pt/documents/overview/sitagliptin-sun-epar-medicine-overview_pt.pdf)

română (RO) (187 KB - PDF)

**First published:**

17/01/2022

[View](/ro/documents/overview/sitagliptin-sun-epar-medicine-overview_ro.pdf)

slovenčina (SK) (188.75 KB - PDF)

**First published:**

17/01/2022

[View](/sk/documents/overview/sitagliptin-sun-epar-medicine-overview_sk.pdf)

slovenščina (SL) (187.87 KB - PDF)

**First published:**

17/01/2022

[View](/sl/documents/overview/sitagliptin-sun-epar-medicine-overview_sl.pdf)

Suomi (FI) (166 KB - PDF)

**First published:**

17/01/2022

[View](/fi/documents/overview/sitagliptin-sun-epar-medicine-overview_fi.pdf)

svenska (SV) (167.19 KB - PDF)

**First published:**

17/01/2022

[View](/sv/documents/overview/sitagliptin-sun-epar-medicine-overview_sv.pdf)

Sitagliptin SUN : EPAR - Risk management plan summary

English (EN) (122.17 KB - PDF)

**First published:** 17/01/2022

[View](/en/documents/rmp-summary/sitagliptin-sun-epar-risk-management-plan-summary_en.pdf)

## Product information

Sitagliptin SUN : EPAR - Product Information

English (EN) (491.55 KB - PDF)

**First published:** 17/01/2022

**Last updated:** 10/11/2025

[View](/en/documents/product-information/sitagliptin-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-133)

български (BG) (642.31 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/bg/documents/product-information/sitagliptin-sun-epar-product-information_bg.pdf)

español (ES) (485.17 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/es/documents/product-information/sitagliptin-sun-epar-product-information_es.pdf)

čeština (CS) (600.94 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/cs/documents/product-information/sitagliptin-sun-epar-product-information_cs.pdf)

dansk (DA) (580.71 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/da/documents/product-information/sitagliptin-sun-epar-product-information_da.pdf)

Deutsch (DE) (553 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/de/documents/product-information/sitagliptin-sun-epar-product-information_de.pdf)

eesti keel (ET) (550.62 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/et/documents/product-information/sitagliptin-sun-epar-product-information_et.pdf)

ελληνικά (EL) (695.58 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/el/documents/product-information/sitagliptin-sun-epar-product-information_el.pdf)

français (FR) (548.15 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/fr/documents/product-information/sitagliptin-sun-epar-product-information_fr.pdf)

hrvatski (HR) (568.75 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/hr/documents/product-information/sitagliptin-sun-epar-product-information_hr.pdf)

íslenska (IS) (542.56 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/is/documents/product-information/sitagliptin-sun-epar-product-information_is.pdf)

italiano (IT) (573.64 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/it/documents/product-information/sitagliptin-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (625.43 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/lv/documents/product-information/sitagliptin-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (633.11 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/lt/documents/product-information/sitagliptin-sun-epar-product-information_lt.pdf)

magyar (HU) (624.06 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/hu/documents/product-information/sitagliptin-sun-epar-product-information_hu.pdf)

Malti (MT) (662.04 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/mt/documents/product-information/sitagliptin-sun-epar-product-information_mt.pdf)

Nederlands (NL) (578.96 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/nl/documents/product-information/sitagliptin-sun-epar-product-information_nl.pdf)

norsk (NO) (532.79 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/no/documents/product-information/sitagliptin-sun-epar-product-information_no.pdf)

polski (PL) (624.36 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/pl/documents/product-information/sitagliptin-sun-epar-product-information_pl.pdf)

português (PT) (563.12 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/pt/documents/product-information/sitagliptin-sun-epar-product-information_pt.pdf)

română (RO) (533.87 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/ro/documents/product-information/sitagliptin-sun-epar-product-information_ro.pdf)

slovenčina (SK) (601.81 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sk/documents/product-information/sitagliptin-sun-epar-product-information_sk.pdf)

slovenščina (SL) (616.01 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sl/documents/product-information/sitagliptin-sun-epar-product-information_sl.pdf)

Suomi (FI) (556.19 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/fi/documents/product-information/sitagliptin-sun-epar-product-information_fi.pdf)

svenska (SV) (556.89 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sv/documents/product-information/sitagliptin-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290396 22/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sitagliptin SUN : EPAR - All authorised presentations

English (EN) (78.7 KB - PDF)

**First published:** 17/01/2022

**Last updated:** 10/11/2025

[View](/en/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-432)

български (BG) (103 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/bg/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (58.41 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/es/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (91.82 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/cs/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (81.02 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/da/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (82 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/de/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (82.35 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/et/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (103.47 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/el/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (60.72 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/fr/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (105.65 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/hr/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (80.22 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/is/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.09 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/it/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (101.13 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/lv/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (104.97 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/lt/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (104.06 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/hu/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (99.66 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/mt/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (79.92 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/nl/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (80.81 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/no/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (101.28 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/pl/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (84.73 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/pt/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (97.14 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/ro/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (104.28 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sk/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (105.35 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sl/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (80.72 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/fi/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (79.23 KB - PDF)

**First published:**

17/01/2022

**Last updated:**

10/11/2025

[View](/sv/documents/all-authorised-presentations/sitagliptin-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sitagliptin SUN Active substance sitagliptin fumarate International non-proprietary name (INN) or common name sitagliptin fumarate Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BH01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve glycaemic control:

as monotherapy: - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with: - metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with: - a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Sitagliptin SUN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/005741

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

Opinion adopted 14/10/2021 Marketing authorisation issued 09/12/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sitagliptin SUN : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.49 KB - PDF)

**First published:** 26/02/2025

**Last updated:** 10/11/2025

[View](/en/documents/procedural-steps-after/sitagliptin-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sitagliptin SUN : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (86.38 KB - PDF)

**First published:** 27/10/2022

**Last updated:** 26/02/2025

[View](/en/documents/procedural-steps-after/sitagliptin-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sitagliptin SUN : EPAR - Public assessment report

Adopted

Reference Number: EMA/611380/2021

English (EN) (518.26 KB - PDF)

**First published:** 17/01/2022

[View](/en/documents/assessment-report/sitagliptin-sun-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Sitagliptin SUN

Adopted

Reference Number: EMA/CHMP/570740/2021

English (EN) (157.03 KB - PDF)

**First published:** 14/10/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-sitagliptin-sun_en.pdf)

#### News on Sitagliptin SUN

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021) 15/10/2021

**This page was last updated on** 10/11/2025

## Share this page

[Back to top](#main-content)